Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure
- 27 August 2002
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 106 (9), 1055-1057
- https://doi.org/10.1161/01.cir.0000030935.89559.04
Abstract
Background— Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in patients with CHF. Methods and Results— Thirty-four subjects with CHF receiving the maximum recommended doses of ACE inhibitors for a duration of 3 to 105 months were studied. The pressor response to exogenous angiotensin I (AI) was measured and normalized for the pressor response to angiotensin II (AII) to assess inhibition of the vascular converting enzyme (AII/AI ratio). Aldosterone levels were determined by solid-phase radioimmunoassay. Eleven of the 34 subjects had plasma aldosterone levels above the upper limit of normal, ie, >15.0 ng/dL. Seven of these 11 subjects (64%) had an AII/AI ratio ≤0.05, indicating complete inhibition of the vascular converting enzyme. In the entire cohort, the AII/AI ratio did not correlate with the duration of ACE inhibitor therapy. Conclusions— Plasma aldosterone levels are elevated in patients with CHF during long-term ACE inhibitor therapy despite complete inhibition of the vascular converting enzyme. Complete inhibition of the vascular converting enzyme does not obviate the need for aldosterone receptor blockade in patients with CHF.Keywords
This publication has 13 references indexed in Scilit:
- Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failureJournal of the American College of Cardiology, 2002
- Vasoconstriction is determined by interstitial rather than circulating angiotensin IIBritish Journal of Pharmacology, 2002
- Aldosterone in Congestive Heart FailureThe New England Journal of Medicine, 2001
- Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotypeJournal of the American College of Cardiology, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999
- How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?Heart, 1999
- Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarctionThe Lancet, 1999
- WITHIN-PATIENT VARIABILITY OF HORMONE AND CYTOKINE CONCENTRATIONS IN HEART FAILUREPharmacological Research, 1998
- Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion.JCI Insight, 1997
- Value of Different Clinical and Biochemical Correlates to Assess Angiotensin Converting Enzyme InhibitionJournal of Cardiovascular Pharmacology, 1994